Spruce Biosciences, Inc. (SPRB)

58.74 +0.81 (+1.40%) USD  |  NASDAQ  |  Sep 08, 11:51
More

Spruce Biosciences Cash and Short Term Investments (Quarterly) : 96.30M for June 30, 2026

Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for SPRB.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 96.30M
March 31, 2026 54.08M
December 31, 2025 48.91M
September 30, 2025 10.67M
June 30, 2025 16.39M
March 31, 2025 25.62M
December 31, 2024 38.75M
September 30, 2024 60.06M
June 30, 2024 69.68M
March 31, 2024 81.15M
December 31, 2023 96.34M
September 30, 2023 108.03M
June 30, 2023 120.52M
March 31, 2023 118.58M
Date Value
December 31, 2022 79.29M
September 30, 2022 90.40M
June 30, 2022 93.30M
March 31, 2022 91.35M
December 31, 2021 88.97M
September 30, 2021 92.32M
June 30, 2021 109.22M
March 31, 2021 148.63M
December 31, 2020 157.15M
September 30, 2020 72.16M
June 30, 2020 36.60M
March 31, 2020
December 31, 2019 3.924M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Biogen, Inc. 1.285B
PTC Therapeutics, Inc. 2.229B
ACADIA Pharmaceuticals, Inc. 956.47M
Alnylam Pharmaceuticals, Inc. 3.308B
Anika Therapeutics, Inc. 38.41M